Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IDEXX LABORATORIES INC /DE Director's Dealing 2017

Feb 9, 2017

30016_dirs_2017-02-09_c49c0cfd-1da6-4f85-80ed-09165918361e.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2017-02-08

Reporting Person: AYERS JONATHAN W (Director, Chairman, President & CEO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2017-02-08 Common Stock M 36250 $26.655 Acquired 1026736 Direct
2017-02-08 Common Stock S 31494 $141.5474 Disposed 995242 Direct
2017-02-08 Common Stock S 4756 $142.1945 Disposed 990486 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-02-08 Non-Qualified Stock Option (right-to-buy) $26.6550 M 36250 Disposed 2017-02-13 Common Stock (36250) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 98000 Indirect

Footnotes

F1: Includes 55 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on December 31, 2016.

F2: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3: Represents the weighted average sales price of the shares sold ranging from a low of $141.02 to a high of $142.02 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F4: Represents the weighted average sales price of the shares sold ranging from a low of $142.03 to a high of $142.83 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F5: Grant of option to buy 78,125 shares of IDEXX Laboratories, Inc. common stock that became exercisable in four annual installments of 16,000 shares each beginning on February 14, 2011 and as to the remaining 14,125 shares on February 14, 2015, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

F6: Not applicable.